Basic fibroblast growth factor and the complexity of tumour angiogenesis

Bibliography

• RAK J, KERBEL RS: bFGF and tumor angiogenesis back in the limelight? Nature Med. (1997) 3 (10) :1083–1084.
   Google Scholar
• FOLKMAN J: Tumor angiogenesis: therapeutic implica-tions. New Engl. J. Med. (1971) 285:1182–1186.
   PubMed Web of Science ®Google Scholar
• SHING Y, FOLKMAN J, SULLIVAN R et al: Heparin affin-ity: purification of a tumor-derived capillary endothe-lial cell growth factor. Science (1 9 8 4) 2 2 3(4642)1296–1299.
   Google Scholar
• WELLSTEIN A, CZUBAYKO F: Inhibition of fibroblast growth factors. Breast Cancer Res. Treat. (1996) 38 (1):109–119.
   PubMed Web of Science ®Google Scholar
• JAIN RK, SCHLENGER K, HOCKEL M, YUAN F: Quantita-tive angiogenesis assays: progress and problems. Na-ture Med. (1997) 3(11):1203–1208.
   PubMed Web of Science ®Google Scholar
• HORI A, SASADA R, MATSUTANI E et al: Suppression of solid tumor growth by immunoneutralizing mono-clonal antibody against human basic fibroblast growth factor. Cancer Res. (1991) 51:6180–6184.
   PubMed Web of Science ®Google Scholar
• WANG Y, BECKER D: Antisense targeting of basic fibro-blast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nature Med. (1997) 3 (8) 887–893.
   PubMed Web of Science ®Google Scholar
• RISAU W: What, if anything, is an angiogenic factor? Cancer Metastasis Rev. (1996) 15:149–151.
   Google Scholar
• BAIRD A, KLAGSBRUN M: The fibroblast growth factor family. Cancer Cells (1991) 3 (6) :239–243.
   PubMed Web of Science ®Google Scholar
• SCHWEIGERER L, NEUFELD G, FRIEDMAN J et al.: Capil-lary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Na-ture (1987) 325:257–259.
   PubMed Web of Science ®Google Scholar
• D'AMORE PA: Modes of FGF release in vivo and in vitro.Cancer Metastasis Rev. (1990) 9(3) :227–238.
   Google Scholar
• CZUBAYKO F, LIAUDET-COOPMAN EDE, AIGNER A et al. A secreted FGF-binding protein can serve as the angio-genic switch in human cancer. Nature Med. (1997) 3(10) 1137–1140
   PubMed Web of Science ®Google Scholar
• VLODAVSKY I, MIAO HQ, MEDALION B, DANAGHER P,RON D: Involvement of heparan sulfate and related molecules in sequestration and growth promoting ac-tivity of fibroblast growth factor. Cancer Metastasis Rev. (1996) 15(2):177–186.
   PubMed Web of Science ®Google Scholar
• KANDEL J, BOSSY-WETZEL E, RADVANYI F et al.: Neovas-cularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell (1991) 66:1095–1104.
   PubMed Web of Science ®Google Scholar
• MATSUZAKI K, YOSHITAKE Y, MATUO Y, SASAKI H, NISHIKAWA K: Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalid-ity of the antibodies for tumor angiogenesis. Proc. Nati Acad. ScL USA (1989) 86(24):9911–9915.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI TP, ROSSANT J: Fibroblast growth factorsin mammalian development. Curr. Opin. Genet. Dev. (1995) 5(4):485–491.
   PubMed Web of Science ®Google Scholar
• ZHOU M, SUTLIFF RL, PAUL RJ et al.: Fibroblast growthfactor 2 control of vascular tone. Nature Med. (1998) 4(2):201–207.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Clinical applications of research on angio-genesis. New Engl. J. Med. (1995) 333:1757–1763.
   PubMed Web of Science ®Google Scholar
• MATTERN J, KOOMAGI R, VOLM M: Coexpression ofVEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density. Anticancer Res. (1997) 17(3C):2249–2252.
   Google Scholar
• PEPPER MS, FERRARA N, ORCI L, MONTESANO R: Potentsynergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. (1992) 189:824–831.
   PubMed Web of Science ®Google Scholar
• GOTO F, GOTO K, WEINDEL K, FOLKMAN J: Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab. Invest. (1993) 69:508–517.
   PubMed Web of Science ®Google Scholar
• ASAHARA T, BAUTERS C, ZHENG LP et al: Synergistic ef-fect of vascular endothelial growth factor and basic fi-broblast growth factor on angiogenesis in vivo. Circulation (1995) 92:365–371.
   Web of Science ®Google Scholar
• KOLCH W, MARTINY-BROWN G, KIESER A, MARNI D: Regulation of the expression of VEGFNPS and its re-ceptors: role in tumor angiogenesis. Breast Cancer Res. Treat. (1995) 36:139–155.
   PubMed Web of Science ®Google Scholar
• STAVRI GT, ZACHARY IC, BASKERVILLE PA, MARTIN JF, ERUSALIMSKY JD: Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Circula-tion (1995) 92:11–14.
   PubMed Web of Science ®Google Scholar
• MANDRIOTA SJ, PEPPER MS: Vascular endothelial growth factor-induced in vitro angiogenesis and plas-minogen activator expression are dependent on en-dogenous basic fibroblast growth factor. J. Cell ScL (1997) 110(Pt. 18):2293–2302.
   PubMedGoogle Scholar
• FRIEDLANDER M, BROOKS PC, SHAFFER RW et al.: Defini-tion of two angiogenic pathways by distinct a, in-tegrins. Science (1995) 270:1500
   PubMed Web of Science ®Google Scholar
• RELF M, LEJEUNE S, SCOTT PA et al.: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotro-phin in human primary breast cancer and its relation to angiogenesis. Cancer Res. (1997) 57(5)963–969.
   Google Scholar
• BROOKS PC, STROMBLAD S, KLEMKE R et al: Antiin-tegrin abl33 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. (1995) 96:1815–1822.
   PubMed Web of Science ®Google Scholar
• HYDER SM, MURTHY L, STANCEL GM: Progestin regula-tion of vascular endothelial growth factor in human breast cancer cells. Cancer Res. (1998) 58(3):392–395.
   PubMed Web of Science ®Google Scholar
• BOUCK N, STELLMACH V, HSU SC: How tumors become angiogenic. Adv. Cancer Res. (1996) 69:135–174.
   PubMed Web of Science ®Google Scholar
• HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumori-genesis. Cell (1996) 86:353–364.
   PubMed Web of Science ®Google Scholar
• DAVIS S, ALDRICH TH, JONES PF et al: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell (1996) 87:1161–1169.
   PubMed Web of Science ®Google Scholar
• MAISONPIERRE PC, SURI C, JONES PF et al.: Angiopoietin-2, a natural antagonist for TIE2 that dis-rupts in vivo angiogenesis. Science (1997) 277:55–60.
   PubMed Web of Science ®Google Scholar
• MACKEY MC, GLASS L: Oscillation and chaos in physio-logical control systems. Science (1977) 197 (4300)287-289. Janusz Rak & Robert S Kerbel
   Google Scholar